This article is on the PSMA track for prostate cancer. If you have a neuroendocrine tumour, the DOTATATE/PRRT track covers a different treatment path.
If you are a man under 60 with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), lutetium Lu-177 vipivotide tetraxetan (Pluvicto) - a radioligand therapy - may fit your case. But younger patients face two issues older men rarely confront: how to fit this therapy into a longer treatment sequence, and what it may mean for your fertility.
Why Younger Men With mCRPC Face Different Decisions
Prostate cancer before age 60 is less common than cancer diagnosed later in life. But when it does occur at a younger age, the disease often behaves differently. Early-onset prostate cancer is more likely to involve inherited mutations in DNA repair genes - particularly BRCA2. A study in the National Institutes of Health PMC archive on germline mutations in early-onset prostate cancer found that more than half of patients in an early-onset cohort carried germline mutations in DNA repair genes.
These mutations affect treatment in two ways. They may be linked to more aggressive disease. And they may open access to PARP inhibitor drugs - a class of targeted therapy that is only appropriate when specific mutations are present. This means the treatment map for a man in his late forties with mCRPC may look meaningfully different from the map for a man in his seventies with the same diagnosis.
Younger men with mCRPC also have more years ahead. What treatment options may still be available after this line ends matters just as much as what might work now.
How Lu-177 PSMA Works and Who Qualifies
Lu-177 PSMA therapy is a type of radioligand therapy. A targeting molecule is engineered to find PSMA - prostate-specific membrane antigen - a protein found on the surface of most prostate cancer cells. Lutetium-177, a radioactive isotope, is attached to this molecule. When the molecule binds to PSMA on a cancer cell, the radiation it carries damages that cell from the inside, while largely sparing surrounding healthy tissue.
Before starting this treatment, you need a PSMA-PET scan to confirm that your tumours express enough PSMA to be targeted. If you have not had this scan yet, our guide on preparing for your PSMA-PET scan for Lu-177 eligibility explains what the process involves and how results are interpreted.
In March 2022, the US Food and Drug Administration approved lutetium Lu-177 vipivotide tetraxetan for adults with PSMA-positive mCRPC who had previously received at least one androgen receptor pathway inhibitor (ARPI) and at least one taxane-based chemotherapy regimen, as confirmed on the FDA approval page. The agency has since expanded this indication to cover patients earlier in their treatment history.
The pivotal VISION trial - a randomised phase 3 study - found that adding Lu-177 PSMA-617 to best standard of care extended median overall survival from 11.3 months to 15.3 months, as reported in the published trial results. Roughly 46% of patients achieved a PSA response, which means the therapy does not work for everyone, regardless of age.
Treatment Sequencing: A Bigger Decision at Younger Ages
Sequencing means choosing the order in which you use your available therapies. For a man in his late seventies with mCRPC, the remaining options may already be limited. For a man in his forties or fifties, there may be additional effective treatment lines still ahead - and a poorly timed choice can close doors that might otherwise stay open.
Updated ASCO systemic therapy guidelines for mCRPC recommend that patients with BRCA1 or BRCA2 mutations who have not yet received an ARPI may benefit from combination ARPI plus PARP inhibitor therapy before Lu-177 PSMA. For patients who have had both an ARPI and taxane chemotherapy, Lu-177 PSMA or cabazitaxel may be appropriate as the next step. The correct order depends heavily on genomic testing results and what you have already received.
Questions to raise with your oncologist before setting a Lu-177 PSMA start date:
- Have I used all available ARPI agents in the mCRPC setting?
- Has germline and somatic genetic testing been done to check for BRCA2, ATM, and related mutations?
- How fast is my PSA rising, and does that rate change when treatment should start?
- Are there open clinical trials worth exploring before committing to a standard line?
For more on how the rate of PSA rise affects the timing decision, our article on what your PSA doubling time means for Lu-177 PSMA eligibility covers what oncologists monitor and why it matters for scheduling.
Fertility and Lu-177 PSMA: What You Should Know
This section is most relevant if you are under 45, have not yet completed your family, or are uncertain whether you may want children in the future. This is a conversation that often does not happen during a standard oncology appointment - but it needs to happen before your first infusion, not after.
Lutetium-177 is a radioactive substance. When it circulates through your body during and after treatment, it exposes all tissues - including the testes - to low-level radiation. This may temporarily affect the cells that make sperm.
Published clinical data indicate that Lu-177 PSMA therapy can lead to a measurable decrease in inhibin-B - a hormone produced by sperm-making cells - and a corresponding rise in FSH (follicle-stimulating hormone). These are markers of reduced testicular function during treatment. According to a retrospective analysis of age-related outcomes in Lu-177 PSMA therapy published in PMC, fertility is generally expected to recover within 12 to 18 months after the final treatment cycle. However, recovery is not guaranteed for every patient - and that distinction matters for a man in his forties.
The American Cancer Society recommends that men discuss fertility preservation before starting any treatment that may affect sperm production. For men considering radioligand therapy, this conversation should happen before the first infusion.
Most treatment centres advise using reliable contraception during Lu-177 PSMA treatment and for at least two months after your last dose. This reduces any possibility of conception during the period when radiation is still clearing from your body.
Sperm Banking Before Lu-177 PSMA: What You Need to Know
Sperm cryopreservation - commonly called sperm banking - is the most accessible fertility preservation option for men before cancer treatment. You provide semen samples at a fertility clinic, and the staff freezes and stores them for potential future use. The process typically takes one to two clinic visits and can usually be arranged within the days between diagnosis and treatment start.
A clinical review of sperm banking for cancer patients published in PMC identifies cryopreservation as a primary option for men facing treatments that may reduce fertility. The review notes average costs of approximately USD 1,000 for initial analysis and freezing, with annual storage fees of around USD 300 to 500. Insurance coverage varies widely depending on your country and plan.
If you are planning to travel to India for Lu-177 PSMA treatment, arrange sperm banking in your home country before you travel. Coordinating across international fertility clinics is simpler to handle during planning than later on. Ask your referring oncologist for a reproductive medicine referral as early as possible in your treatment planning process.
ADT, Bone Health, and Long-Term Effects for Younger Men
Androgen deprivation therapy (ADT) is almost always continued alongside Lu-177 PSMA treatment. The evidence supporting this practice is reviewed in our article on continuing ADT during Lu-177 PSMA therapy and what the evidence shows.
For younger men, the long-term effects of sustained low testosterone matter more than they do for older patients. Extended ADT accelerates bone density loss and affects energy and mood over time. If you have been on ADT for more than 12 months, ask your care team whether a DEXA bone density scan is appropriate and whether bone-protective medication should be added to your plan.
Some patients managing long-term ADT also ask about over-the-counter options for bone and joint support alongside their medical treatment. If that is part of your care conversation, discuss any supplements with your oncologist before starting anything new.
Does Being Younger Affect How Well Lu-177 PSMA Works?
Evidence on this question is still developing. A study examining men diagnosed with mCRPC at or before age 55 who then received Lu-177 PSMA after prior chemotherapy found that this group tended to have more aggressive disease at the point of starting radioligand therapy, as reported in the NIH PMC archive. More aggressive baseline disease does not necessarily predict a worse response to Lu-177 PSMA, but it does underscore the value of a careful eligibility evaluation before committing to a treatment course.
A separate age-stratified retrospective analysis found that patients under 65 showed markedly improved median overall survival with Lu-177 PSMA compared to older patients receiving the same therapy. This may partly reflect better baseline health and fitness in younger patients rather than a direct age-treatment effect - but it does suggest that younger patients should not assume they are weaker candidates for this therapy.
The most important factor is not your age. It is whether your tumours express PSMA on imaging, what prior therapies you have had, and whether your kidney function and blood counts can support the treatment. If you are weighing eligibility and would like a second opinion on your scans before committing to treatment, ask your oncologist for a referral to a nuclear medicine specialist.
Do Not Skip Genetic Testing
If you have not yet had germline genetic testing, ask for it before making any radioligand therapy decision. A blood test can identify inherited mutations in genes like BRCA2, BRCA1, and ATM. Men who develop prostate cancer before age 60 carry these mutations at higher rates than men diagnosed later in life, and the results directly affect which treatment classes are most likely to help and in what order they should be used.
A positive result may also matter for your close biological relatives. A genetic counsellor can walk you through what the findings mean for your treatment sequence and what your family members may want to know about their own inherited risk.
When to Talk to Your Doctor
Raise these points with your oncologist or care team:
- You are under 60 with mCRPC and want to map out all current options before deciding on Lu-177 PSMA.
- You have not yet had a PSMA-PET scan to confirm eligibility for radioligand therapy.
- You have not had germline and somatic genetic testing for BRCA2 and related mutations.
- You have not spoken with anyone about fertility preservation or sperm banking before starting cancer treatment.
- You have been on ADT for over a year and have not had a bone density assessment.
- You are considering travelling for treatment and want to understand the full process before committing.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
Can men under 60 qualify for Lu-177 PSMA therapy?
Yes. Age alone does not disqualify you from Lu-177 PSMA therapy. The key eligibility requirements are having PSMA-positive mCRPC confirmed on a PSMA-PET scan, prior treatment with at least one ARPI agent, and prior taxane-based chemotherapy - under the original FDA-approved indication for adults. More recent FDA label expansions may allow earlier use. Kidney function, blood counts, and overall fitness also factor into eligibility. An oncologist or nuclear medicine specialist should review your specific case.
Does Lu-177 PSMA therapy permanently affect fertility?
The effect is generally expected to be temporary. Published clinical data show that Lu-177 PSMA therapy can cause a decrease in inhibin-B and a rise in FSH - both signs of reduced sperm-making activity - during and shortly after treatment. These changes are typically expected to reverse within 12 to 18 months after the final dose. However, recovery is not guaranteed for every patient. If having children in the future is important to you, discuss sperm banking with your care team before your first infusion.
Should I bank sperm before starting Lu-177 PSMA treatment?
Yes, if there is any possibility you may want biological children after treatment. Sperm banking is straightforward, can typically be done in one to two clinic visits, and should happen before your first treatment cycle - not after. The process can usually be completed within the timeframe between a cancer diagnosis and treatment start. Ask your oncologist for a referral to a reproductive medicine specialist as early as possible in your planning.
How does treatment sequencing differ for men under 60 with mCRPC?
Younger, fitter patients often have more treatment lines still potentially available ahead of them. If you carry a BRCA2 or BRCA1 mutation, PARP inhibitor therapy may be recommended before or instead of radioligand therapy, depending on your prior treatment history. Clinical trial eligibility may also be higher in younger patients. Your oncologist needs to weigh the potential benefit of Lu-177 PSMA now against which options it would leave open - a calculation that is more complex at age 50 than at age 75. Genomic testing is the starting point for this conversation.
Is Lu-177 PSMA less effective in younger men with aggressive early-onset disease?
Not necessarily. Some retrospective data suggest that patients under 65 may have improved overall survival outcomes with Lu-177 PSMA compared to older patients, though this may partly reflect better baseline fitness. Early-onset mCRPC can be more biologically aggressive, but PSMA expression on imaging, prior therapy history, and organ function are more predictive of response than age alone. A thorough eligibility assessment is important for all patients, regardless of age.
What does a BRCA2 mutation mean for my treatment options in mCRPC?
A BRCA2 or BRCA1 mutation may make you eligible for PARP inhibitor drugs - a class of targeted therapy that works by blocking a DNA repair pathway that cancer cells with these mutations rely on. Updated ASCO guidelines recommend testing for these mutations in all patients with mCRPC. Depending on what prior treatments you have had, combination ARPI plus PARP inhibitor therapy may be recommended before Lu-177 PSMA. A genetic counsellor can help interpret your results and their implications for treatment sequence and family risk.
